Business Context and Reporting Period
This Form 8-K, dated August 17, 2026, serves as a supplement to the Joint Proxy Statement/Prospectus regarding the proposed merger of equals between Huntsman Corporation and Olin Corporation. The filing was issued to voluntarily amend disclosures in response to stockholder complaints and demand letters alleging material omissions. The Huntsman Board continues to unanimously recommend that stockholders vote "FOR" the merger proposal, with special meetings scheduled for August 25, 2026.
Key Financial Metrics and Projections
The filing provides detailed financial data used by financial advisors (Lazard, Citi, and Morgan Stanley) to value the transaction as of March 31, 2026, and June 12, 2026.
- Huntsman Standalone Projections (2026-2030):
- Revenue: Projected to grow from $6,150 million in 2026 to $8,066 million in 2030.
- Adjusted EBITDA: Projected to increase from $501 million in 2027 to $1,160 million in 2030.
- Unlevered Free Cash Flow: Projected to range from $114 million in 2027 to $648 million in 2030.
- Balance Sheet Items (as of March 31, 2026):
- Huntsman Net Debt: Approximately $1,698 million to $2,067 million (varies by advisor methodology).
- Huntsman Cash: Approximately $369 million.
- Olin Net Debt: Approximately $2,804 million to $3,016 million.
- Olin Cash: Approximately $192 million.
- Implied Equity Value Ranges (Per Share):
- Huntsman: Ranges from $7.20 to $21.80 depending on the advisor and methodology (DCF vs. Public Market Analysis).
- Olin: Ranges from $29.00 to $56.30 depending on the advisor and methodology.
Material Changes and Disclosures
The filing amends the Joint Proxy Statement/Prospectus to clarify the following:
- Financial Advisor Methodologies: Added clarifications regarding how Lazard, Citi, and Morgan Stanley selected comparable companies, calculated discount rates, and handled tax attributes and pension contributions.
- Comparable Company Multiples: Updated tables showing Enterprise Value (EV) to Adjusted EBITDA multiples for selected peers in the chemicals and firearms industries for 2026E, 2027E, and 2028E.
- Projections Updates: Clarified that updates to Huntsman's standalone projections were primarily mechanical (non-operating assumptions, cash flow definitions) rather than changes in business outlook. 2026E revenue was reduced slightly from $6,287 million to $6,150 million.
- Revenue Synergies: Explicitly stated that no estimates of revenue synergies were prepared by management.
- Advisor Holdings: Confirmed Lazard held no proprietary shares of Huntsman or Olin as of June 15, 2026.
Guidance, Risks, and Contingencies
Legal Contingencies: The filing addresses two complaints filed in New York Supreme Court and one in Missouri Circuit Court by purported stockholders. These complaints allege negligent misrepresentation and material omissions in the proxy statement. While the companies believe the allegations are without merit, they are supplementing disclosures to avoid delaying the merger.
Risks: The filing reiterates standard forward-looking statement risks, including the possibility that the transaction may not close, failure to achieve synergies, regulatory approval delays, stockholder litigation, and general economic or industry downturns affecting the chemical sector.
Management Commentary: Management maintains that the Joint Proxy Statement/Prospectus complies with all applicable laws and that the supplemental disclosures are voluntary measures to minimize distraction and expense.
Investor Verification Checklist
- Verify the status of the pending stockholder lawsuits in New York and Missouri and any potential impact on the August 25, 2026, special meetings.
- Review the updated "Huntsman Standalone Projections" table to confirm the revised 2026 revenue guidance of $6,150 million.
- Examine the specific valuation ranges provided by Citi, Lazard, and Morgan Stanley to understand the spread in implied equity values ($7.20–$21.80 for Huntsman).
- Confirm the absence of revenue synergy estimates in the transaction rationale.
- Check the updated comparable company multiples for the chemicals industry to assess market valuation context.